AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02522299 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELLIPTA
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters
Study NCT01050699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
Study NCT01050699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Fentanyl
Description: Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.~Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)~Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)
Study NCT02430597 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
Study NCT02430597 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT03029611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03029611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gynecological Surgical Procedure
Description: Undergo cytoreductive surgery
Study NCT03029611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03029611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03029611 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine
Description: Given ID
Study NCT03987672 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Assess the nutritional effects of the Kate Farm Peptide 1.5 nutritional Formula
Description: Kate Farm Peptide 1.5 nutritional Formula
Study NCT01532024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microdose of NAP
Description: Delivery of NAP at microdose (\<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT00942578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 intravenous (IV) over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
Study NCT00942578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10 mg orally every day
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02896868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered IV.
Study NCT02896868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT03961776 — intervention group
Intervention type: DEVICE
Intervention: MRI-guided radiotherapy by on-board DWI sequences
Description: The radiotherapy treatment will be delivered on the MRI-guided radiotherapy platform. The on-board DWI sequences will be performed every three fractions in addition to the treatment session and will last approximately 3-4 minutes.
Study NCT02758054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
Study NCT01023269 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: InterStim Therapy
Description: Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
Study NCT03080194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate
Description: Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
Study NCT03080194 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Subject in control group will be applied with oral antipsychotics or other conventional medication.
Study NCT02400710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician-Supported PTSD Coach
Description: Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
Study NCT02400710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Managed PTSD Coach
Description: One 10 minute session explaining how to use the PTSD Coach mobile app.
Study NCT03137082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine XR 3mgs/daily
Description: Guanfacine 3mg tablet
Study NCT03137082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for guanfacine)
Description: Sugar pill manufactured to mimic guanfacine tablets
Study NCT00417599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: lifestyle intervention .
Study NCT00417599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: waiting list control group
Study NCT02922959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Intervention
Description: The Peer Intervention is a 20-minute telephone call delivered by a Peer Interventionist, who is trained to answer questions about the content of the personally-tailored information packets. The primary goal of the call is for the participant and the Peer Interventionist to have an open exchange of information about medication-assisted treatment (MAT) for opioid use disorder.
Study NCT02922959 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naloxone nasal spray kit
Description: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
Study NCT02922959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naloxone nasal spray kit
Description: Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
Study NCT02922959 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personally-tailored opioid overdose prevention education (information packet)
Description: Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder.
Study NCT02922959 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personally-tailored opioid overdose prevention education (information packet)
Description: Personally-tailored information packet with three participant-specific reports (Personal Overdose Risk Factors Report; Medication Assisted Treatment (MAT) Report; and the Opioid Overdose Information Report), and general written information about opioid overdose and treatment for opioid use disorder.
Study NCT04898725 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 4800IU daily
Study NCT01928784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy 2000 impulses
Description: Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
Study NCT01928784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radial Extracorporeal Shock Wave Therapy 4000 impulses
Description: Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
Study NCT01779947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Vaginal Tablets 10 mcg
Study NCT01779947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Vaginal Tablets 10 mcg
Study NCT01779947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03348982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jogging program
Description: The intervention is a 12-week jogging program consisting of 24 sessions (two sessions per week, 30 min per session).
Study NCT02200133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Survivorship Care Plan (SCP)
Description: The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
Study NCT00887627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conivaptan hydrochloride
Description: intravenous
Study NCT04486183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: capillary blood samples
Description: The patient's finger was wiped with alcohol, left to dry, and the first and second blood drops were read The patient was asked to wash their hands, their finger was perforated with a strip, and the first and second blood drops were read The finger of the patient whose hands had been washed was wiped with alcohol, left to dry, and the first and second blood drops were read Venous blood was collected for blood sugar measurement 2 hours after the patient had a beverage containing 75 gr sugar for OGTT The patient was ensured to wash their hands, their finger was wiped with alcohol, and the first and second blood drop glucose values were measured and recorded
Study NCT02439606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glide Rite Rigid Stylet group
Description: Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
Study NCT02439606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Parker Flex-It directional stylet group
Description: Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
Study NCT03140306 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Patients who have had split dose CT
Description: Computed tomography
Study NCT02208583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel & Prednisone
Description: Docetaxel \& Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
Study NCT02208583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DP & Targeted drugs
Description: Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
Study NCT02208583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin & Etoposide
Description: cisplatin \& Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
Study NCT02208583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP & Targeted drugs
Description: cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
Study NCT03361514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported Protocolized Discontinuation (SPD)
Description: Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
Study NCT03361514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supported Protocolized Discontinuation (SPD)
Description: Patients who choose to discontinue their medication will make a personal tapering schedule with their GP based upon a discontinuation protocol with tapering suggestions. The protocol offers suggestions to taper within a maximum of 6 months describing all types of available dosages per antidepressant so individualized schedules can be constructed. In addition, they will be offered supportive meetings with the GP's mental health assistant. The assistant will receive basic information about discontinuation guidance, i.e. the information brochure, decision aid, discontinuation protocol and a short guideline how to organise consultations.
Study NCT03361514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy (MBCT)
Description: In addition to the SPD patients are offered Mindfulness Based Cognitive Therapy (MBCT) in homogeneous groups of patients willing to withdraw from their medication. MBCT will be offered according to the treatment protocol developed for recurrent depression, adaptated to the specific needs of patients discontinuing their antidepressant medication. The mindfulness courses will be provided by teachers qualifying the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders. All teachers will receive additional training in using the specific study protocol at the start of the project.
Study NCT01427348 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: with assistant
Description: head extension by an assistant during direct laryngoscopy
Study NCT03751280 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-004
Description: PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
Study NCT01427348 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without assistant
Description: without head extension by an assistant during direct laryngoscopy
Study NCT02350491 — intervention group
Intervention type: OTHER
Intervention: Collection of biological samples
Description: collection of biologic samples ( blood and urine) befor and after woman pregnacy
Study NCT03751280 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: PEAR-004 (an investigational digital therapeutic) or sham (control) was downloaded to the subject's phone and then the assigned application was unlocked using a prescription code provided by Pear Therapeutics. As this was a digital therapeutic device study, dose or mode of administration is not applicable.
Study NCT03287947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: Oral nintedanib, taken twice daily
Study NCT03556345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.5 mg/kg IV every 2 weeks
Study NCT01306409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cera, darbepoetin, epoetin-beta
Description: Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
Study NCT01306409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESA
Description: Sequential application of three different ESA
Study NCT02970721 — intervention group
Intervention type: DRUG
Intervention: Antipsychotic
Description: Antipsychotic monotherapy
Study NCT02000635 — intervention group
Intervention type: OTHER
Intervention: Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day
Study NCT03357068 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control side will receive only perforations on recipient site, which is the conventional technique for bone blocks graft.
Study NCT03357068 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acid
Description: Test side will receive treatment with citric acid (10%) for 30s at bone block surface and recipient site
Study NCT02970721 — intervention group
Intervention type: DRUG
Intervention: Antidepressant
Description: Antidepressant monotherapy
Study NCT02970721 — intervention group
Intervention type: DRUG
Intervention: Antipsychotic and Antidepressant
Description: Polytherapy
Study NCT01994135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reference food
Description: Reference food will be used to which test food samples will be compared to.
Study NCT01994135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food dose 1
Description: Will contain low dose of a mixture of polyphenols in addition to the reference food
Study NCT01994135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test food dose 2
Description: Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
Study NCT04728659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel 0.075 MG
Description: It will be given orally for 3 to 5 days during FSH administration for ovarian stimulation
Study NCT04728659 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran
Description: It will be given subcutaneously for 3 to 5 days during FSH administration for ovarian stimulation
Study NCT03044951 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryoballoon ablation
Description: cryoballoon ablation：pulmonary vein isolation by cryoballoon
Study NCT03044951 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
Study NCT03973125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
Study NCT03995537 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood sample
Description: Samples will be collected at the inclusion and repeated if necessary before LT, including one 4 mL EDTA sample and one 4 mL Heparin sample and one 2.5 mL PAXgene® sample, allowing the HLA-DR assay to be performed with also plasma aliquots and messenger RNAs.~Same samples will also be collected :~* between inclusion and LT in case of major clinical change~* During the pre-transplant follow-up 3 months after inclusion, for patients who have not been transplanted within 3 months after inclusion~* at day 1 after LT~* 2 times a week after the LT for a maximum of 1 month~Biological data will be collected at those different times.
Study NCT02042989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.~Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase.
Study NCT05872633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-management intervention
Study NCT05872633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care-as-usual
Study NCT04083248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feasibility group
Description: Same as arm description
Study NCT02979873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include (i) flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and (ii) proteomics assay (research labs).